

Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

I Widengård, O Mäepea, A Alm

Abstract

Aim—To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined.

Methods—22 patients with open angle glaucoma or ocular hypertension were included in a 4 week open label study. Median age was 68 years (range 50–79). They were allocated to either 2 weeks' treatment with once daily evening administration of latanoprost monotherapy (50 µg/ml) or twice daily dipivefrin monotherapy (1 mg/ml), followed by 2 weeks' combination therapy with both drugs.

Results—Latanoprost alone reduced IOP from 19.3 (SD 1.4) to 14.8 (0.9) mm Hg ($p < 0.01$). Addition of dipivefrin caused a further reduction to 12.4 (0.9) mm Hg ($p < 0.01$ compared with latanoprost alone). In the group where the treatment started with dipivefrin IOP was reduced from 22.3 (1.2) to 18.4 (1.0) mm Hg ($p < 0.01$) and with the combination to 14.9 (0.9) mm Hg ($p < 0.01$). No change in aqueous flare was observed with either drug, alone or in combination. A slight increase in conjunctival hyperaemia was observed when the two drugs were combined.

Conclusions—Latanoprost and dipivefrin have an additive effect on IOP and no clinically significant effect on the permeability to proteins of the blood-aqueous barrier. This implies that the two drugs can be a useful combination for the treatment of glaucoma.

(Br J Ophthalmol 1998;82:404–406)

Latanoprost, a prostaglandin $F_{2\alpha}$ analogue^{1 2} has recently been introduced as an ocular hypotensive agent. Recent large studies have shown it to be a potent agent in patients with glaucoma or ocular hypertension.^{3–6} It has also been suggested that the ocular hypotensive effect of adrenaline may be at least partly mediated by an endogenous production of prostaglandins.^{7 8} Thus, both from a theoretical and a clinical point of view it would be of interest to determine the effect on intraocular pressure (IOP) of the combination of a prostaglandin analogue and an adrenergic agonist.

A further reason to study this combination is the possibility that the two drugs combined could have an effect on the permeability of the blood-aqueous barrier. In the rabbit low doses of naturally occurring prostaglandins reduce

IOP while high doses cause an increased IOP with a breakdown of the blood-aqueous barrier.⁹ The eyes of cats and monkeys are much more resistant and a similar breakdown of the blood-aqueous barrier was not observed even after repeated topical application of prostaglandins.¹⁰ In previous clinical studies latanoprost monotherapy had no effect on aqueous flare.^{11 12} Adrenergic agonists may also affect the permeability of the blood-aqueous barrier. Thus chronic stimulation of the sympathetic nerves in rabbits causes a breakdown of the blood-aqueous barrier that seems to be mediated by prostaglandins.¹³ A small prostaglandin mediated increase in the blood-aqueous barrier permeability to sodium fluorescein was reported after treatment with adrenaline for 2 months or more in human eyes,¹⁴ and Araie *et al* reported a biphasic response of the blood-aqueous barrier in human eyes to a single dose of phenylephrine; an initial marked increase in aqueous flare followed by a decrease.¹⁵ The present study was performed to evaluate the effect of latanoprost and dipivefrin, either individually or in combination, on IOP and on the blood-aqueous barrier in patients with open angle glaucoma or ocular hypertension.

Materials and methods

This was a 4 week open label randomised study. The study protocol was approved by the Swedish regulatory authority and the local ethics committee. The study was performed in accordance with the revised Declaration of Helsinki (Hong Kong 1989). Each patient gave written informed consent before entry into the study.

Patients with unilateral or bilateral open angle glaucoma, capsular glaucoma, or ocular hypertension (a prestudy IOP of at least 22 mm Hg) were included. If both eyes fulfilled the eligibility criteria, the right eye was designated as the study eye. There was a wash-out period of previous treatment in the study eye of 2 weeks for adrenergic agonists, 5 days for cholinergic agonists or oral carbonic anhydrase inhibitors, and 3 weeks for β adrenergic blockers.

Exclusion criteria included an IOP of >35 mm Hg on current treatment, concomitant medication known to affect IOP, pregnancy, a history of acute angle closure, or severe dry eye syndrome, intraocular surgery or argon laser trabeculoplasty within the previous 6 months, current use of contact lenses, ocular inflammation/infection within the previous 15

Department of
Ophthalmology,
University Hospital,
Uppsala, Sweden
I Widengård
O Mäepea
A Alm

Correspondence to:
Albert Alm, MD,
Department of
Ophthalmology, University
Hospital, S-751 85 Uppsala,
Sweden.

Accepted for publication
5 November 1997

Table 1 Patient demographics

	Lat/Dip*	Dip/Lat†	All
Mean age (range)	69 (50–79)	68 (60–74)	68 (50–79)
Sex (M/F)	8/3	7/4	15/7
Diagnosis			
POAG	8	4	12
Capsular glaucoma	1	3	4
OH	2	4	6
Previous glaucoma treatment	11	9	20

*Group that started with latanoprost with dipivefrin added after 2 weeks' treatment.

†Treatment was initiated with dipivefrin.

Table 2 IOP (mean (SEM)) at baseline and after 2, 3, and 4 weeks' treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

Treatment	Day 0	Day 14	Day 21	Day 28
Lat/Dip	19.3 (1.4)	14.8 (0.9)	12.1 (0.9)	12.4 (0.9)
Dip/Lat	22.3 (1.2)	18.4 (1.0)	13.2 (0.7)	14.9 (0.9)

Table 3 Aqueous flare as photon counts (mean (SEM)) at baseline and after 2, 3, and 4 weeks' treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

Treatment	Day 0	Day 14	Day 21	Day 28
Lat/Dip	10.4 (1.1)	8.6 (1.0)	9.8 (1.1)	9.6 (1.3)
Dip/Lat	7.4 (1.1)	7.2 (0.8)	7.4 (0.9)	7.2 (0.6)

Table 4 Hyperaemia score (mean (SEM)) obtained by comparing with a set of standard photographs from none (0) to severe (3) at baseline and after 2, 3, and 4 weeks' treatment for patients who started treatment with latanoprost (Lat/Dip) or dipivefrin (Dip/Lat)

Treatment	Day 0	Day 14	Day 21	Day 28
Lat/Dip	0.59 (0.12)	0.64 (0.14)	0.95 (0.16)	1.00 (0.20)
Dip/Lat	0.45 (0.13)	0.59 (0.16)	1.00 (0.18)	1.18 (0.19)

months, and any condition preventing reliable applanation tonometry.

The study comprised five visits; a prestudy evaluation within 1 month of study start followed by randomisation to treatment at baseline (day 0), and evaluations on days 14, 21, and 28. After randomisation, patients were allocated to treatment with 2 weeks of monotherapy with latanoprost or dipivefrin, followed by 2 weeks of combined therapy with both drugs. Latanoprost 50 µg/ml was administered once daily in the evening (9 pm). Dipivefrin (dipivalyl adrenaline) 1 mg/ml was administered in the morning (9 am) and in the evening (9 pm). During combined therapy, patients were instructed to instil the two eyedrops 5 minutes apart.

IOP was determined with a Goldmann tonometer at 9 am. The mean of three consecutive readings was used for analysis. Flare was determined with the Kowa laser flare meter (Kowa FM500). Ten readings were made, the highest and the lowest values were discarded and the mean of the remaining eight values was used for analysis. Evaluation of conjunctival hyperaemia (none = 0, mild = 1, moderate = 2, severe = 3) was performed using standard photographs. Routine clinical examinations of the eyes, including determination of visual acuity and refraction, slit lamp examination, and ophthalmoscopy were performed at each visit. All examinations were performed before applying the next dose at 9 am, 12 hours after the previous dose. To avoid optical interference caused by the application of fluorescein and the tonometer probe, flare was measured before IOP.

STATISTICAL ANALYSIS

Statistical significance of changes in IOP and flare between each examination was evaluated with the paired *t* test within the treatment groups and with the *t* test between the treatment groups. Mean (SEM) are presented. The change in hyperaemia score between each examination was tested with the sign test within the treatment groups, and with the Wilcoxon rank sum test between the two treatment groups. All statistical tests were performed at the 5% level.

Results

Twenty two patients were included in the study, all of whom completed the 4 week treatment period. The demographic characteristics of the study population are shown in Table 1. In general, there were no major differences in patient characteristics between the two treatment groups. Even though the patients were assigned randomly there was a difference in IOP at baseline (day 0) between treatment groups of 3 mm Hg.

Table 2 presents the IOP for each examination in the two treatment groups. Latanoprost alone reduced morning IOP with 4.5 (1.2) mm Hg ($p < 0.01$) from 19.3 mm Hg. Adding dipivefrin caused a further reduction of 2.3 (0.6) mm Hg on day 28 ($p < 0.01$). Combined, the two drugs reduced IOP with 6.9 mm Hg (35%, $p < 0.0001$) on day 28.

Dipivefrin alone reduced morning IOP with 3.9 (1.1) mm Hg ($p < 0.01$) from 22.3 mm Hg. Adding latanoprost caused a further reduction of 3.6 (0.5) mm Hg on day 28 ($p < 0.0001$). In this group the two drugs combined caused an IOP reduction from baseline of 7.4 mm Hg (33%, $p < 0.0001$).

Table 3 presents photon count values. In each group the highest mean values were observed on baseline and neither drug, alone or combined, caused a significant change in flare values. Compared with baseline, flare values on day 28 were increased in seven patients, unchanged in two, and decreased in 13 patients with a range from an increase of 6.5 photon counts to a reduction of 7.1. In addition, slit lamp evaluation of flare and cells revealed no clinically significant effects of treatment.

Hyperaemia scores are presented in Table 4. At baseline mean hyperaemia was graded between none and mild, and no change occurred when either drug was applied alone. With the two drugs combined the hyperaemia score almost doubled ($p < 0.05$), but the average hyperaemia was still judged to be mild. Moderate hyperaemia, grade 2, was observed in five of 22 patients on the last examination.

No change in refraction or visual acuity was observed. Mild punctate corneal erosions were observed in two eyes on day 28; one untreated eye and one that had been treated with dipivefrin for 4 weeks with latanoprost added for the last 2 weeks.

Discussion

A majority of the patients included in this study had a diagnosis of open angle glaucoma.

There was no lower IOP limit for inclusion of patients with established glaucoma, and the mean baseline IOP in the two groups was only 19 and 22 mm Hg respectively. One can expect less effect on IOP, both in absolute and relative terms, with a low initial IOP. Still, both latanoprost and dipivefrin caused statistically highly significant reductions in IOP when applied alone. Moreover, a statistically significant further reduction in IOP was observed when the two drugs were combined for the last 14 days of the study with an added reduction of 16% for dipivefrin and 19% for latanoprost. These results do not indicate that a possible prostaglandin mediated effect of adrenaline, as reported by Camras *et al.*,⁷ diminishes the effect of latanoprost. A solution of 50 µg/ml is at the top of the dose-response curve for latanoprost.¹⁶ Prostaglandin effects are mediated by a family of receptors and latanoprost is a rather selective agonist for one of them, the FP receptor.¹ Thus, in the event that prostaglandin receptors are involved in the ocular hypotensive effect of adrenaline one may speculate that other prostaglandin receptors than the FP receptor are involved.

An additive effect of 19% when latanoprost is added to dipivefrin is of clinical interest since the number of clinically useful combinations including dipivefrin is limited; a reduction of IOP of 20% or more can mainly be expected by adding a full dose of acetazolamide, judged from early experience of combining adrenaline and acetazolamide.¹⁷ The effect of adding dipivefrin to timolol results, as expected, in only a small or no additive effect on IOP,^{18, 19} while combining dipivefrin and pilocarpine can only be expected to give a modest additive effect; the effect of combining 2% pilocarpine and 1% adrenaline resulted in an IOP that was 12% lower than with pilocarpine alone.²⁰

Neither latanoprost nor dipivefrin, alone or combined, caused any increase in flare as evaluated with the laser flare meter. Previous studies with quantitative evaluation of flare have not shown any effect for either latanoprost^{11, 12} or adrenaline,²¹ but a slight increase in the permeability of the blood-aqueous barrier to fluorescein was reported after 2 months' treatment with adrenaline in human eyes.¹² This effect seemed to be mediated by prostaglandins since it was prevented by indomethacin. Fluorescein is a small molecule that normally passes through the blood-aqueous barrier slowly and the change in the barrier permeability necessary to cause a slight increase in fluorescein permeation is probably of no clinical relevance. It is also unlikely that the effect is mediated by the FP receptor. In rabbits prostaglandin induced breakdown of the blood-aqueous barrier occurs mainly with agents that have a high affinity for the EP₂ receptor, and FP receptor agonists do not disrupt the barrier.²² As latanoprost has little or no affinity for the EP₂ receptor¹ it is not surprising that we found no effect on aqueous flare.

Both latanoprost and dipivefrin were very well tolerated either alone or in combination. A slight increase in conjunctival hyperaemia was

observed in some patients following combination treatment. However, this was mild and did not require the cessation of treatment.

In conclusion, both latanoprost and dipivefrin reduced IOP effectively in patients with open angle glaucoma or ocular hypertension. Whether given alone or in combination they had no measurable effect on the permeability of the blood-aqueous barrier to proteins. Moreover, the combination of latanoprost and dipivefrin had an additive effect on IOP reduction and was well tolerated. This implies that the combination of latanoprost and dipivefrin should prove an effective and safe addition to the current treatment options for glaucoma.

- 1 Stjernschantz J, Resul B. Phenyl-substituted prostaglandin analogs for glaucoma treatment. *Drugs Future* 1992; 17:691-704.
- 2 Resul B, Stjernschantz J, No K, *et al.* Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. *J Med Chem* 1993;36:243-8.
- 3 Alm A, Stjernschantz J, the Swedish Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily evening or morning. A comparison with timolol. *Ophthalmology* 1995;102:1743-52.
- 4 Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. *Ophthalmology* 1996; 103:138-47.
- 5 Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month randomised, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. *Ophthalmology* 1996;103:126-37.
- 6 Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12 week study. *Arch Ophthalmol* 1996;114:929-32.
- 7 Camras CB, Feldman SG, Podos SM, *et al.* Inhibitors of the epinephrine-induced reduction of intraocular pressure by systemic indomethacin in humans. *Am J Ophthalmol* 1985; 100:169-75.
- 8 Anderson L, Wilson WS. Inhibition of indomethacin of the increased facility of outflow induced by adrenaline. *Exp Eye Res* 1990;50:119-26.
- 9 Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. *Invest Ophthalmol Vis Sci* 1977;16:1125-34.
- 10 Bito LZ, Draga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. *Invest Ophthalmol Vis Sci* 1983;24:312-9.
- 11 Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F₂ analogue, after topical application in normal and ocular hypertensive human eyes. *Arch Ophthalmol* 1993;111: 1351-8.
- 12 Hotehama Y, Mishima HK. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F₂-isopropyl ester analogues for glaucoma treatment. *Jpn J Ophthalmol* 1993; 37:259-69.
- 13 Bartels SP, Pawlowski AM. Chronic electrical stimulation of sympathetic nerves: effects on blood-aqueous barrier. *Curr Eye Res* 1990;9:927-34.
- 14 Miyake K, Miyake Y, Kuratomi R. Long-term effects of topically applied epinephrine on the blood-aqueous barrier in humans. *Arch Ophthalmol* 1987;105:1360-63.
- 15 Araie M, Mori M, Oshika T. Effect of topical phenylephrine on the permeability of the blood-aqueous barrier in man. *Graefes Arch Clin Exp Ophthalmol* 1992;30:171-4.
- 16 Alm A, Villumsen J, Tornquist P, *et al.* Intraocular pressure reducing effect of PhXA41 in ocular hypertensive agents—a one-month study. *Ophthalmology* 1993;100: 1312-7.
- 17 Becker B. Additive effect of epinephrine and acetazolamide in control of intraocular pressure. *Am J Ophthalmol* 1958;75:639-42.
- 18 Parrow KA, Hong YJ, Shin DH, Shi DX, McCarty B. Is it worthwhile to add dipivefrin HCl 0.1% to topical beta-1-, beta-2-blocker therapy? *Ophthalmology* 1989;96:1338-42.
- 19 Morrison JC, Robin AL. Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. *Ophthalmology* 1989;96:3-7.
- 20 Brounley DW. A comparison of pilocarpine hydrochloride and epinephrine bitartrate. *Ann Ophthalmol* 1971;3:970-3.
- 21 Mori M, Sakurai M, Araie M. Effect of topical epinephrine on permeability of blood-aqueous barrier in human eyes. *Jpn J Ophthalmol* 1992;36:342-7.
- 22 Protzman CE, Woodward DF. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP₂ receptor subtype. *Invest Ophthalmol Vis Sci* 1990;31:2463-6.